"AstraZeneca enhances long-term growth through Oncology investment in Acerta Pharma
17 December 2015
Transaction includes late-stage, potential best-in-class irreversible small molecule BTK inhibitor, acalabrutinib
Opportunity for first regulatory submissions in haematological malignancies in 2016
Investment establishes in-house expertise in blood cancers and complements strategic use of immunotherapy in haematological malignancies and solid tumours
17 December 2015 __________________________________________________